"The U.S. Food and Drug Administration today expanded the approved use of Xgeva (denosumab) to treat adults and some adolescents with giant cell tumor of the bone (GCTB), a rare and usually non-cancerous tumor.
GCTB generally occurs in a"...
(pancrelipase) Delayed-Release Capsules, Buffered and Enteric-Coated Microspheres.
- Patient Information:
Details with Side Effects
PANCRECARB® (pancrelipase) contain buffered pancreatic enzymes: lipase, amylase and protease, isolated and concentrated from porcine pancreatic glands. The enzyme containing microspheres are coated with a pH sensitive enteric-coating to provide protection against gastric inactivation of the buffer-stabilized enzymes during gastric passage.
EACH PANCRECARB® (pancrelipase) CONTAINS:
|Lipase||4,000 U.S.P. Units||8,000 U.S.P. Units|
|Amylase||25,000 U.S.P. Units||40,000 U.S.P. Units|
|Protease||25,000 U.S.P. Units||45,000 U.S.P. Units|
Inactive ingredients include sodium carbonate, sodium bicarbonate, cellulose acetate phthalate, diethyl phthalate, gelatin, sodium carboxymethyl starch, polyvinylpyrrolidone, talc, ursodiol, and other trace ingredients.
Last reviewed on RxList: 1/20/2009
This monograph has been modified to include the generic and brand name in many instances.
Additional Pancrecarb Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.